Oulin Biological's Class 1.1 new drug recombinant golden yeast vaccine completed the enrollment of all subjects in Phase III clinical trials.

Recently, the important progress has been made in the cooperation research and development of the "National Class 1.1 New Drug - Recombinant Staphylococcus aureus Vaccine" between Orlin Biotech and the Army Medical University of the Chinese People's Liberation Army. The Phase III clinical trial has completed the enrollment of all subjects, marking the entry of the product development into the final sprint stage.